R&D News | pharmaphorum

News

Genentech confirms Magargee as permanent CEO

Roche’s Genentech unit has looked internally for its new chief executive, appointing Ashley Magargee to the role following the departure of Alexander Hardy last month.

News

Digitised pathology resource will speed HIV cancer R&D

A collection of clinical specimens that has been gathered from people living with HIV for almost 30 years has been given a digital makeover with the help of computational

News

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

Not content with taking on the respiratory syncytial virus (RSV) prevention market with its antibody-based therapy Beyfortus, AstraZeneca has agreed to buy US biotech Icos

News

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

Sanofi’s anti-CD38 antibody Sarclisa has struggled to make headway against Genmab and Johnson & Johnson’s rival Darzalex since it was first approved for multiple myelo

News

MSD, Moderna take mRNA jab into phase 3 for lung cancer

MSD and partner Moderna have started a late-stage trial of their personalised cancer vaccine V940 as a combination with MSD’s PD-1 inhibitor Keytruda for patients with non

News

ASH: AZ’s danicopan shows long-term benefit in PNH

New data with AstraZeneca’s oral Factor D inhibitor danicopan have built the case for the drug as an add-on to complement C5 antibodies for the treatment of paroxysmal noc

Genentech confirms Magargee as permanent CEO

Digitised pathology resource will speed HIV cancer R&D

AZ agrees $1.1bn deal to buy RSV jab developer Icosavax

ASH: Sanofi’s Sarclisa carves out a multiple myeloma niche

MSD, Moderna take mRNA jab into phase 3 for lung cancer

ASH: AZ’s danicopan shows long-term benefit in PNH

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks